Gelesis Holdings Debt to Equity Ratio 2021-2022 | GLS

Current and historical debt to equity ratio values for Gelesis Holdings (GLS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Gelesis Holdings debt/equity for the three months ending September 30, 2022 was 5.89.
Gelesis Holdings Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $0.13B $-0.00B -37.31
2022-06-30 $0.13B $0.01B 26.26
2022-03-31 $0.14B $0.01B 14.23
2021-12-31 $0.48B $-0.33B -1.44
2021-09-30 $0.32B $-0.04B -7.24
2021-06-30 $0.27B $0.01B 54.40
2021-03-31 $0.27B $0.01B 54.43
2020-12-31 $0.00B 0.00
2020-09-30 $0.27B $0.01B 54.47
2020-06-30 $0.00B $0.00B 8.87
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.012B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00